Related by context. All words. (Click for frequent words.) 77 clinically meaningful improvement 69 clinically meaningful reductions 68 UPDRS motor 68 PASI scores 67 CIMZIA ™ 67 statistically significant improvement 66 plus methotrexate 66 Secondary endpoints 66 timepoints 66 tipranavir r 66 tapentadol ER 65 NIHSS 65 NLX P# 65 Unified Parkinson Disease 65 hour bronchodilation 65 EDSS scores 65 certolizumab 65 teriflunomide 65 ATACAND 65 glycated hemoglobin levels 65 Psoriasis Area 64 symptomatic VTE 64 #mg dose [001] 64 intravascular hemolysis 64 oxycodone CR 64 ADCS CGIC 64 pyridostigmine 64 timepoint 64 8mg/kg 64 SGRQ 64 OAB symptoms 64 APTIVUS r 64 baseline HbA1c 64 poststroke 64 ADAS Cog 64 levodopa therapy 64 desvenlafaxine succinate 64 neurologic progression 63 mitoxantrone plus 63 dosage regimens 63 FOLPI 63 liver histology 63 methotrexate monotherapy 63 FFNS 63 AGILECT R 63 IOP lowering 63 GAMMAGARD 63 HDRS 63 Primary endpoints 63 somatostatin analog 63 RAPAFLO R 63 elevated ALT 63 acromegalic patients 63 tumor regressions 63 psychosocial variables 63 ACTEMRA TM 63 serologically active SLE 63 plus MTX 63 bortezomib refractory 63 PSA nadir 63 relapsed MM 63 FAMPYRA 63 intermittent dosing 63 β blockers 63 HRQL 63 severe exacerbations 63 PRADAXA #mg 63 etanercept 63 WOMAC pain 63 CIMZIA TM certolizumab pegol 63 intraocular inflammation 62 urate lowering 62 glycosylated hemoglobin HbA1c 62 Alequel 62 inhaled iloprost 62 MACUGEN 62 serum phosphate levels 62 Postoperatively 62 parkinsonian symptoms 62 WBPA 62 morphometric vertebral fractures 62 achieved ACR# 62 alemtuzumab treated 62 analgesic efficacy 62 euthymic patients 62 subthreshold depression 62 CDAI 62 HbA 1c 62 #mg/day [001] 62 Secondary endpoints include 62 nasal symptom 62 pramipexole 62 mg kg dose 62 mesalamine granules 62 briakinumab 62 pulmonary exacerbations 62 clinically meaningful 62 intracerebral haemorrhage 62 HAQ DI 62 ruboxistaurin 62 MMSE score 62 dopaminergic therapy 62 Subgroup analyzes 62 left ventricular diastolic 62 mg administered orally 62 anemia hemoglobin 62 NYHA functional class 62 methacholine challenge 62 rosuvastatin #mg 62 Doxil ® 62 achieved statistical significance 62 PsA 62 antithrombotic therapy 62 virologic breakthrough 62 hematologic parameters 62 posttreatment 62 CTEPH 62 complete cytogenetic response 62 DLQI 62 Visual Analog Scale 62 Natalizumab 62 rFVIIa 62 adjunctive placebo 62 QoL 62 eculizumab therapy 62 prospectively stratified 62 EDSS score 61 visceral metastases 61 dose proportionality 61 moderate renal impairment 61 CIMZIA TM 61 venlafaxine XR 61 MADRS score 61 CCyR 61 Secondary endpoints included 61 statistically significant efficacy 61 ropivacaine 61 CR CRu 61 tolterodine 61 zonisamide SR 61 vasomotor symptoms 61 inflammatory biomarkers 61 adenotonsillectomy 61 aspartate aminotransferase AST 61 AGILECT ® 61 secondary efficacy endpoints 61 Flu Cy 61 incontinence episodes 61 riociguat 61 Scale EDSS 61 overt nephropathy 61 pentoxifylline 61 levodopa induced 61 Crohn Disease Activity 61 mg BID 61 rotigotine 61 gout flares 61 NATRECOR ® 61 fluticasone salmeterol 61 weekly subcutaneous injections 61 artery stenosis 61 hematological parameters 61 extrapyramidal symptoms 61 adalimumab 61 virological response 61 schizophrenia CIAS 61 serum urate levels 61 sustained virological response 61 pCR 61 basal bolus regimen 61 EDARBI 61 placebo controlled clinical 61 oral diclofenac 61 EVIZON 61 genotypic resistance 61 HIV HCV coinfected 61 dose cohort 61 aminotransferases 61 tolvaptan 61 gross hematuria 61 postprocedure 61 salmeterol fluticasone 61 postintervention 61 neurocognitive deficits 61 tolterodine ER 61 glycosylated hemoglobin levels 61 secondary endpoint 61 INCB# [003] 61 HbA1c levels 61 safinamide 61 RLAI 61 clinically meaningful efficacy 61 solifenacin 61 pretreatment baseline 61 placebo controlled clinical trials 61 hemoglobin A1c levels 61 neurologic symptoms 61 thromboembolic events 61 demonstrated clinically meaningful 61 UPDRS scores 61 ICD shocks 61 TEAEs 61 ibandronate 61 neuropsychiatric symptoms 61 neurocognitive function 61 haematologic 61 HRQoL 61 alanine aminotransferase ALT 61 VaD 61 macroalbuminuria 61 definite stent thrombosis 61 COPAXONE R 61 symptom severity 61 VELCADE melphalan 61 NNT = 61 baminercept 61 hypoglycemic events 61 FOLFOX4 61 fasting plasma glucose FPG 61 Hp2 2 60 Fibromyalgia Impact Questionnaire 60 BENICAR 60 nonvertebral fracture 60 antiarrhythmic drug 60 elevated creatinine 60 HRQOL 60 nighttime awakenings 60 transaminase elevations 60 efficacy endpoint 60 biochemical relapse 60 paricalcitol 60 serum cortisol 60 ADAS cog 60 RoACTEMRA 60 HbA 1c levels 60 pharmacokinetic parameters 60 4mg/kg 60 DAS# CRP 60 UPDRS 60 Oncophage vaccination 60 KRAS mutations occur 60 inhaled treprostinil 60 octreotide LAR 60 nadroparin 60 asthma exacerbation 60 ritonavir boosted 60 hemodialysis patients 60 QTc prolongation 60 retinal thickness 60 trastuzumab Herceptin ® 60 immunomodulatory agents 60 ADCS ADL 60 intravenous diuretics 60 #mg/day [002] 60 PREZISTA r arm 60 mg/m2 dose 60 mcg Albuferon 60 Lantus ® 60 budesonide pMDI 60 intravitreal injections 60 tocilizumab 60 ALT flares 60 favorable tolerability 60 hyperalgesia 60 DAPT 60 pharmacokinetic characteristics 60 intratympanic 60 maximal doses 60 INVEGA ® 60 conventional DMARDs 60 oral FTY# 60 intact parathyroid hormone 60 recurrent DVT 60 lymphocyte counts 60 ADAGIO study 60 RECIST Response Evaluation Criteria 60 Hepatotoxicity 60 enthesitis 60 sipuleucel T 60 thrombocytopenic patients 60 underwent resection 60 crizotinib PF # 60 autonomic dysfunction 60 comparator arm 60 levodopa induced dyskinesia 60 CYP#D# inhibitor 60 corticosteroid dose 60 antiplatelet medication 60 posttransplant 60 undetectable HBV DNA 60 mcg BID 60 ispinesib administered 60 colorectal adenoma 60 antidepressant efficacy 60 P = .# 60 tolerability profiles 60 mg dose 60 abatacept 60 inflammatory lesions 60 mucosal healing 60 tumor histology 60 6MWD 60 underwent liver transplantation 60 efalizumab 60 #mg doses [002] 60 oral olanzapine 60 RECIST criteria 60 subscore 60 impaired cognition 60 Subgroup analysis 60 KAPIDEX 60 glucocorticoid therapy 60 atherogenic dyslipidemia 60 achieved CCyR 60 REMINYL ® 60 symptomatic intracranial 60 concomitant AEDs 60 efficacy tolerability 60 prednisone prednisolone 60 annualized relapse 60 bardoxolone methyl 60 gait disturbances 60 nondiabetic patients 60 Brief Psychiatric 60 eplerenone 60 placebo dexamethasone 60 complete cytogenetic 60 lipid lowering agents 60 pamidronate 60 hsCRP levels 60 QTcF 60 Health Assessment Questionnaire 60 prospectively enrolled 60 SSRI SNRI 60 CRp 60 HBeAg positive patients 60 hematologic toxicity 60 ALT elevations 60 aMCI precursor 60 decitabine 60 Traficet EN 60 pharmacodynamic PD 60 BPH symptom 59 Pharmacokinetic studies 59 FOLPI regimen 59 eszopiclone 59 MMSE scores 59 tiotropium 59 EXJADE 59 chronic GVHD 59 CIPN 59 systolic BP 59 virologic response 59 oral anticoagulant therapy 59 ataluren 59 NPH insulin 59 cardiac repolarization 59 prodromal symptoms 59 BoNTA 59 hip BMD 59 hyperphenylalaninemia HPA due 59 radiographic progression 59 REYATAZ r arm 59 HbA1C levels 59 placebo p = 59 gemcitabine carboplatin 59 ACR# responses 59 CANCIDAS 59 platelet reactivity 59 PEG IFN 59 MCyR 59 NIH CPSI 59 mg QD 59 bosentan 59 clomipramine 59 diameter stenosis 59 RLS symptoms 59 Durezol 59 favorable pharmacokinetic profile 59 postmenopausal osteoporotic women 59 ALIMTA cisplatin 59 lumbar spine BMD 59 sUA 59 sweat chloride 59 angiographic outcomes 59 LVEF 59 erythropoietic 59 carotid IMT 59 COPAXONE 59 pegylated liposomal doxorubicin 59 corrected QT interval 59 alfuzosin 59 chemoradiation therapy 59 Index CDAI 59 baseline A1C 59 PANSS scores 59 YMRS 59 tegaserod 59 atazanavir ritonavir 59 pressor response 59 paliperidone ER 59 locoregional disease 59 APTIVUS R 59 MACCE 59 cytogenetic responses 59 ALSFRS R 59 cortical stimulation 59 steroid dexamethasone 59 HBeAg negative patients 59 calcineurin inhibitor 59 Symptom severity 59 IBDQ 59 paclitaxel eluting stents 59 lenalidomide dexamethasone 59 lacosamide 59 LEXIVA r 59 RRMS patients 59 mg ustekinumab 59 pharmacodynamic effects 59 biologic DMARD 59 achieved PASI 59 oral rivaroxaban 59 viral kinetics 59 oral anticoagulation 59 ALA PDT 59 progression TTP 59 octreotide 59 knee osteoarthritis OA 59 lactate dehydrogenase LDH 59 cytogenetic response 59 demonstrated antitumor activity 59 postoperative chemotherapy 59 fasting plasma glucose 59 virologic responses 59 nadolol 59 receiving golimumab 59 CR nPR 59 AGHD 59 subscale scores 59 chronic thromboembolic pulmonary 59 serum phosphate 59 QTc 59 CYPHER Stent 59 systemic corticosteroid 59 #mg dose [002] 59 doxorubicin docetaxel 59 CC genotype 59 interferon ribavirin 59 tumor necrosis 59 TMC# r 59 rimonabant #mg 59 autoantibody positive 59 alicaforsen enema 59 lopinavir r arm 59 premorbid 59 postoperative AF 59 rhGH 59 secondary efficacy endpoint 59 mcg QD 59 exploratory endpoints 59 clinically relevant 59 subscales 59 NMIBC 59 affective psychosis 59 clevidipine 59 exacerbations 59 vitreous haze 59 DAS# remission 59 PROactive study 59 HIF PHI 59 NEVO ™ 59 olanzapine LAI 59 metabolic parameters 59 T2DM 59 #mg QD [002] 59 dalteparin 59 adriamycin 59 cerebrovascular events 59 ginkgo extract 59 partial remissions 59 Insulin PH# 59 euthymic 59 Arikace 59 radiotherapy RT 59 decrements 59 lipid parameters 59 abacavir lamivudine 59 glycated hemoglobin HbA1c 59 nonmetastatic prostate cancer 59 pramlintide 59 ximelagatran 59 endoscopic remission 59 aspartate aminotransferase 59 Febrile neutropenia 59 lymphopenia 59 seropositive patients 59 serum phosphorous 59 radiographic outcomes 59 BPH symptoms 59 statistically significant reduction 59 thromboembolic 59 BENICAR HCT 59 events TEAEs 59 patients evaluable 59 COPD exacerbations 59 insulin degludec 59 quetiapine XR 59 intravenous tPA 59 MitraClip device 59 VAPRISOL 58 RAPTIVA 58 hemodynamic variables 58 dosing cohort 58 pegaptanib 58 Tumor shrinkage 58 oral allopurinol 58 ZOLINZA 58 epoetin beta 58 metastatic CRC 58 cytogenic 58 galiximab 58 #mg BID [001] 58 Clinically significant 58 log# reduction 58 CTAP# Capsules 58 HBeAg seroconversion 58 NMES 58 mycophenolate mofetil 58 Thal Dex 58 ACR# response 58 fosbretabulin 58 Univariate analysis 58 apremilast 58 mild renal insufficiency 58 dose limiting toxicities 58 histologically proven 58 adalimumab Humira 58 chlorambucil 58 hematological toxicity 58 NIHSS score 58 depressive symptom 58 fluticasone furoate 58 tissue oxygenation 58 hemoglobin A1c HbA1c 58 Pharmacokinetic parameters 58 administered subcutaneously 58 Timed Walk 58 psoriatic arthritis PsA 58 Perforomist Inhalation Solution 58 everolimus eluting stents 58 urinary N telopeptide 58 Expanded Disability Status 58 lesional 58 lymphocytosis 58 glomerular filtration 58 laboratory abnormalities 58 + PH# 58 WOMAC 58 baseline PASI 58 weekly intravenous infusions 58 GnRH agonist 58 elevated IOP 58 Severity Index PASI 58 biochemical recurrence 58 FluCAM arm 58 intima media thickness 58 elevated transaminases 58 inotropic 58 Apidra ® 58 PEGylated interferon beta 1a 58 idiopathic Parkinson disease 58 chemoradiotherapy 58 IPL# 58 dosing cohorts 58 MAGE A3 ASCI 58 neovascular 58 CPAP adherence 58 azacytidine 58 antipsychotic efficacy 58 Rating Scale MADRS 58 SSc 58 cisplatin vinorelbine 58 serum concentrations 58 perioperatively 58 AZILECT R 58 evaluable patients 58 dyslipidaemia 58 achieving PASI 58 systolic function 58 Montgomery Åsberg Depression 58 Teriflunomide 58 GH deficiency 58 Non inferiority 58 serum clusterin levels 58 1mg dose 58 OADs 58 receiving ISENTRESS 58 overactive bladder symptoms 58 verteporfin 58 COPAXONE ® 58 FOLFOX6 58 Ejection Fraction 58 neutropaenia 58 bowel resection 58 receiving VELCADE 58 INC# 58 irbesartan 58 ischemic cardiomyopathy 58 ejection fractions 58 prospectively defined 58 idiopathic thrombocytopenic purpura 58 comorbid depression 58 TTF Therapy 58 prednisone prednisolone plus 58 Pemetrexed 58 beta 1a 58 bronchodilatory 58 dyspnoea 58 adjuvant cisplatin 58 androgen deprivation 58 lumiliximab 58 immune thrombocytopenic purpura ITP 58 ARCALYST ® 58 sensory neuropathy 58 urate lowering therapy 58 retinal vein occlusion 58 acetabular dysplasia 58 mCRC patients 58 angiographically 58 atrioventricular block 58 cranial irradiation 58 treprostinil 58 pharmacokinetics PK 58 surgical debulking 58 vidofludimus 58 transaminases 58 mmHg diastolic 58 dosing intervals 58 5-FU/LV 58 serum urate 58 SNT MC# 58 ramelteon 58 perfusion defects 58 alteplase 58 flutamide 58 spirometric 58 goserelin 58 oral clodronate 58 oxcarbazepine 58 DLTs 58 antihypertensive therapy 58 perioperative complications 58 BARACLUDE ® 58 reflux symptoms 58 iniparib 58 pomalidomide 58 QD dosing 58 perfusion abnormalities 58 T2 lesion volume 58 thetreatment 58 recurrent ischemia 58 relapsing MS 58 cardio respiratory fitness 58 orthostatic hypotension 58 deep venous thromboses 58 depressive symptoms 58 bronchial thermoplasty 58 spontaneous bowel movements 58 proliferative retinopathy 58 dose dependently 58 eosinophilia 58 NATRECOR R 58 sustained virologic response 58 CHOP chemotherapy 58 dose atorvastatin 58 Engerix B 58 proliferative diabetic retinopathy 58 Zemplar Capsules 58 aromatase inhibitor therapy 58 pharmacokinetic equivalence 58 antiemetics 58 hypoglycaemic episodes 58 blood Phe 58 placebo controlled trials 58 detectable HCV RNA 58 complete remissions 58 QT QTc 58 divalproex sodium 58 insulin detemir 58 urinary albumin excretion 58 ORENCIA R 58 mitoxantrone 58 unresectable HCC 58 clinicopathological features 58 cholinesterase inhibitor 58 headache nasopharyngitis 58 somatic symptoms 58 visilizumab 58 rilonacept 58 AZILECT 58 tipranavir 58 remission CR 58 mg BID dose 58 olmesartan 58 neuroregenerative 58 antiplatelet 58 bronchial hyperresponsiveness 58 pain palliation 58 HOMA IR 58 #OHD levels 58 GI motility 58 leucopenia 58 pulmonary toxicity 58 thrombotic complications 58 alanine aminotransferase 58 rhinoconjunctivitis 58 fibrinolytic therapy 58 colesevelam HCl 58 WOMAC scores 58 Alzheimer Disease Assessment 58 subsyndromal 58 tamoxifen Nolvadex ® 58 fluvastatin 58 azilsartan medoxomil 58 probiotic supplementation 58 IL 1ß 58 TURBT 58 TNF inhibitor 58 XIENCE V PROMUS Stent 58 PCWP 58 hypogonadal men 58 Myelodysplastic Syndrome MDS 58 SYN# 58 experimentally induced 58 QTc intervals 58 nicardipine 58 non menstrual pelvic 58 carotid stenosis 58 Cimzia TM 58 comorbid disorders 58 depressive symptomatology 57 symptomatic NOH 57 neurosensory 57 MabCampath 57 ACZ# 57 antiangiogenic therapy 57 KRAS status 57 FOLFIRI 57 mycophenolate mofetil MMF 57 serum potassium 57 tacrolimus ointment 57 oral antidiabetic medication 57 cilostazol 57 Neuropsychiatric Inventory NPI 57 azacitidine 57 vaso occlusive crisis 57 Lucentis monotherapy 57 otamixaban 57 INFERGEN 57 aldosterone antagonist 57 Abilify aripiprazole 57 intravenous IV infusion 57 airflow obstruction 57 hepatic encephalopathy HE 57 statistically significant superiority 57 lumbar disk herniation 57 Hypotension 57 abdominal pain abdominal discomfort 57 glargine 57 ocular inflammation 57 aplindore 57 FFR guided treatment 57 immunomodulatory therapy 57 demyelinating 57 splenectomized 57 GOUT 57 TNF alpha inhibitor 57 LV ejection fraction 57 relapsed SCLC 57 platelet inhibition 57 lispro alone 57 MoxDuo TM IR 57 HeFH 57 folinic acid 57 CONCERTA ® 57 PSADT 57 non squamous histology 57 subcutaneous insulin 57 rHuEPO 57 radiochemotherapy 57 bezafibrate 57 Lipitor #mg 57 ACTEMRA 57 intravenous cyclophosphamide 57 peak VO2 57 plasma renin activity 57 heavily pretreated patients 57 serologically active patients 57 binary restenosis 57 Elitek 57 Study GL# 57 null responder HCV 57 intra articular injection 57 Infusion Reactions Severe 57 histological subtypes 57 ER CHOP 57 GERD symptom 57 opioid naïve 57 postoperative complication 57 serum phosphorus 57 tipranavir ritonavir 57 ARIXTRA 57 IFN beta 57 receiving VICTRELIS 57 hemodilution 57 hyperlipidaemia 57 pulmonary exacerbation 57 diabetic gastroparesis 57 Amrubicin 57 unstable angina UA 57 glatiramer acetate 57 IBS C 57 oral antidiabetes 57 antigen PSA levels 57 hemodynamic measurements 57 SCIg 57 DAS# [002] 57 pegylated interferon alfa 2b 57 ProSavin 57 guanfacine extended release 57 Montgomery Asberg Depression 57 docetaxel chemotherapy 57 oral hypoglycemic agent 57 nerve conduction velocity 57 VcMP 57 active comparator 57 microbiological eradication 57 endometrial thickness 57 acute STEMI 57 serum calcium levels 57 Preoperatively 57 mg TID 57 ZACTIMA 57 neurocognitive outcomes 57 beta blocker therapy 57 % CI #.#-#.# [003] 57 carbidopa levodopa 57 ACR# ACR# 57 blood Phe levels 57 maximally tolerated lipid lowering 57 induce remission 57 ecchymosis 57 pertuzumab 57 abiraterone acetate 57 TPV r 57 hypopituitarism 57 FROVA 57 Postoperative 57 induce orthostatic hypotension 57 brivaracetam 57 creatinine levels 57 thromboembolic complications 57 LHON 57 F FDG PET 57 gastroduodenal 57 neuroprotective effects 57 epoetin alpha 57 VIIBRYD 57 PAOD 57 gadolinium enhancing lesions 57 plus prednisone 57 thrombocytosis 57 fasting insulin 57 rituximab refractory 57 conjunctival hyperemia 57 chronic idiopathic thrombocytopenic purpura 57 generalized tonic clonic seizures 57 T1DM 57 relapsed AML 57 low dose cytarabine 57 #mg dose [003] 57 Score DAS 57 intravitreal injection 57 LT NS# 57 intradermal injections 57 idiopathic PD 57 NovoSeven ® 57 BMI z 57 rotigotine transdermal patch 57 Neupro R 57 prior chemotherapy regimens 57 HORIZONS AMI trial 57 caspofungin 57 fondaparinux 57 EOquin TM 57 plasma pharmacokinetics 57 QT intervals 57 SCr 57 adjunctive ABILIFY 57 pharmacokinetic PK profile 57 MYCAMINE 57 adrenalectomy 57 CrCl 57 hypercholesterolaemia 57 canakinumab 57 systolic dysfunction 57 ULORIC 57 CSBM 57 Decitabine 57 intravenous morphine 57 delayed gastric emptying 57 inhaled corticosteroid therapy 57 apnea hypopnea index 57 sacral neuromodulation 57 anticholinergic medications 57 lipid lowering medications 57 paresthesias 57 EDSS 57 coronary stenosis 57 TDF FTC 57 AST ALT 57 overnight polysomnography 57 lixisenatide 57 quetiapine Seroquel 57 baseline FEV 57 lispro 57 SPIRIVA HandiHaler 57 antioxidant supplementation 57 systemic hypotension 57 cardiac autonomic 57 serum aminotransferase levels 57 Rating Scale UPDRS 57 glycosylated hemoglobin 57 Kinoid 57 pharmacodynamic parameters 57 #.#/#.# mmHg [001] 57 peritumoral brain edema 57 trospium 57 serum testosterone 57 NNRTI resistance 57 Secondary efficacy endpoints 57 Glypromate 57 HSCT 57 plasma cortisol 57 argatroban 57 guanfacine 57 ACR# [002] 57 dose titration 57 brain lesions 57 % CI #.#-#.# [007] 57 non splenectomized 57 mcg albinterferon alfa 2b 57 hepatorenal syndrome 57 peginterferon alfa 2a #KD 57 Hb A1C 57 leukocyte count 57 primary aldosteronism 57 mcg doses 57 selegiline 57 lamotrigine 57 Target Lesion Revascularization TLR 57 plasma creatinine 57 dacarbazine chemotherapy 57 ipsilateral stroke 57 vismodegib 57 antiarrhythmic 57 squamous histology 57 daytime alertness 57 Viral load 57 pravastatin therapy 57 response CCyR 57 dyspareunia 57 TNF antagonist 57 Scale PANSS 57 low dose Iluvien 57 recurrent glioblastoma multiforme 57 Visual Analogue Scale VAS 57 Ishak fibrosis score 57 aminotransferase elevations greater 57 LATUDA 57 postoperative mortality 57 clodronate 57 LUTS 57 seroprotection 57 icatibant 57 Scale EDSS score 57 mL/min/#.# m 2 57 Ophena TM 57 serum lipid levels 57 EQ 5D 57 pioglitazone HCl 57 surrogate endpoint 57 creatine supplementation 57 hemostatic efficacy 57 mutated KRAS 57 diabetic polyneuropathy 57 eosinophil count 57 orally inhaled migraine 57 melphalan prednisone